Multiplex Analysis of Serum Biomarkers in Ovarian Cancer Patients Using Bio-Plex Suspension Array System

CA-125 tumor antigen has been the standard for monitoring response of ovarian cancer patients to therapy. However, the use of this marker for detecting ovarian cancer has been limited by both false positive and false negative results. The analysis of novel cancer biomarkers in combination with this established marker as a composite profiling tool is expected to further benefit early detection, screening, and prediction of the disease. In this study, the levels of 37 potential biomarkers were profiled. Eight markers were identified as being highly elevated in ovarian cancer samples compared to age-matched healthy controls.